179 related articles for article (PubMed ID: 33399453)
1. Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.
Sharif EU; Kalisiak J; Lawson KV; Miles DH; Newcomb E; Lindsey EA; Rosen BR; Debien LPP; Chen A; Zhao X; Young SW; Walker NP; Sträter N; Scaletti ER; Jin L; Xu G; Leleti MR; Powers JP
J Med Chem; 2021 Jan; 64(1):845-860. PubMed ID: 33399453
[TBL] [Abstract][Full Text] [Related]
2. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.
Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J
Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451
[TBL] [Abstract][Full Text] [Related]
3. Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.
Rahimova R; Fontanel S; Lionne C; Jordheim LP; Peyrottes S; Chaloin L
PLoS Comput Biol; 2018 Jan; 14(1):e1005943. PubMed ID: 29377887
[TBL] [Abstract][Full Text] [Related]
4. Discovery of AB680: A Potent and Selective Inhibitor of CD73.
Lawson KV; Kalisiak J; Lindsey EA; Newcomb ET; Leleti MR; Debien L; Rosen BR; Miles DH; Sharif EU; Jeffrey JL; Tan JBL; Chen A; Zhao S; Xu G; Fu L; Jin L; Park TW; Berry W; Moschütz S; Scaletti E; Sträter N; Walker NP; Young SW; Walters MJ; Schindler U; Powers JP
J Med Chem; 2020 Oct; 63(20):11448-11468. PubMed ID: 32614585
[TBL] [Abstract][Full Text] [Related]
5. 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
Bhattarai S; Pippel J; Scaletti E; Idris R; Freundlieb M; Rolshoven G; Renn C; Lee SY; Abdelrahman A; Zimmermann H; El-Tayeb A; Müller CE; Sträter N
J Med Chem; 2020 Mar; 63(6):2941-2957. PubMed ID: 32045236
[TBL] [Abstract][Full Text] [Related]
6. CD73-TNAP crosstalk regulates the hypertrophic response and cardiomyocyte calcification due to α1 adrenoceptor activation.
Gan XT; Taniai S; Zhao G; Huang CX; Velenosi TJ; Xue J; Urquhart BL; Karmazyn M
Mol Cell Biochem; 2014 Sep; 394(1-2):237-46. PubMed ID: 24894822
[TBL] [Abstract][Full Text] [Related]
7. Host surface ectonucleotidase-CD73 and the opportunistic pathogen,
Lee JS; Chowdhury N; Roberts JS; Yilmaz Ö
Virulence; 2020 Dec; 11(1):414-429. PubMed ID: 32419582
[TBL] [Abstract][Full Text] [Related]
8. Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.
Wang Y; Wang C; Zhu Y; Zhang Y; Chen B; Wu Y; Yao J; Miao Z
Bioorg Med Chem Lett; 2021 Feb; 34():127758. PubMed ID: 33359608
[TBL] [Abstract][Full Text] [Related]
9. Ecto-5'-nucleotidase, CD73, is an endothelium-derived hyperpolarizing factor synthase.
Ohta M; Toyama K; Gutterman DD; Campbell WB; Lemaître V; Teraoka R; Miura H
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):629-36. PubMed ID: 23288168
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.
Beatty JW; Lindsey EA; Thomas-Tran R; Debien L; Mandal D; Jeffrey JL; Tran AT; Fournier J; Jacob SD; Yan X; Drew SL; Ginn E; Chen A; Pham AT; Zhao S; Jin L; Young SW; Walker NP; Leleti MR; Moschütz S; Sträter N; Powers JP; Lawson KV
J Med Chem; 2020 Apr; 63(8):3935-3955. PubMed ID: 32212732
[TBL] [Abstract][Full Text] [Related]
11. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.
Gong YP; Wan RZ; Liu ZP
Expert Opin Ther Pat; 2018 Feb; 28(2):167-171. PubMed ID: 29166791
[TBL] [Abstract][Full Text] [Related]
14. Elevated ecto-5'-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell disease.
Liu H; Adebiyi M; Liu RR; Song A; Manalo J; Wen YE; Wen AQ; Weng T; Ko J; Idowu M; Kellems RE; Eltzschig HK; Blackburn MR; Juneja HS; Xia Y
Blood Adv; 2018 Aug; 2(15):1957-1968. PubMed ID: 30097462
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
[TBL] [Abstract][Full Text] [Related]
16. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.
Tsukui H; Horie H; Koinuma K; Ohzawa H; Sakuma Y; Hosoya Y; Yamaguchi H; Yoshimura K; Lefor AK; Sata N; Kitayama J
BMC Cancer; 2020 May; 20(1):411. PubMed ID: 32397971
[TBL] [Abstract][Full Text] [Related]
17. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity.
Gao ZW; Wang HP; Lin F; Wang X; Long M; Zhang HZ; Dong K
BMC Cancer; 2017 Feb; 17(1):135. PubMed ID: 28202050
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
19. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
Jeffrey JL; Lawson KV; Powers JP
J Med Chem; 2020 Nov; 63(22):13444-13465. PubMed ID: 32786396
[TBL] [Abstract][Full Text] [Related]
20. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]